{ "schemaVersion": 1, "organisationId": "O-85de2d0558d94a188941262c14a80523", "slug": "royalty-pharma-plc", "name": "Royalty Pharma plc", "updatedAt": "2026-10-02T11:13:45.638182Z", "sections": [ { "type": "OVERVIEW", "text": "Royalty Pharma plc is a life-sciences company that provides funding to drug developers and acquires royalty interests in biopharmaceutical medicines, receiving payments tied largely to product sales. It describes itself as the largest buyer of biopharmaceutical royalties. Founded in 1996, the company’s stated mission is to accelerate life-sciences innovation and positively affect patient lives globally. [P97551930][P146465211][P100719992][https://www.royaltypharma.com/our-firm/]\n\nIts portfolio spans marketed medicines and development-stage candidates across areas including rare diseases, neuroscience, oncology, hematology, immunology, respiratory disease and diabetes. Examples of therapies in its portfolio include Trikafta, Trelegy, Tysabri, Evrysdi and Xtandi. The company’s interests extend to medicines serving patients in global markets; this refers to the reach of the underlying therapies rather than implying a broad corporate office network. [P146465215][T9032949][P70126503]\n\nFor the year ended December 31, 2025, Royalty Pharma reported $2.378 billion in total income and other revenues. A filing-based data source reports 100 employees at year-end 2025. [T7144074][https://stockanalysis.com/stocks/rprx/employees/]\n[P97551930][P146465211][P100719992][https://www.royaltypharma.com/our-firm/][P146465215][T9032949][P70126503][T7144074][https://stockanalysis.com/stocks/rprx/employees/][https://www.royaltypharma.com/our-firm/][https://stockanalysis.com/stocks/rprx/employees/]", "updatedAt": "2026-10-02T11:13:45.638182Z" }, { "type": "PRODUCTS", "text": "Royalty Pharma’s “products” are royalty interests in medicines developed and commercialized by other companies; it does not itself manufacture or market the therapies. Its portfolio includes royalties on more than 35 marketed medicines, including Vertex’s cystic-fibrosis therapies Kalydeco, Orkambi, Symdeko/Symkevi, Trikafta/Kaftrio and Alyftrek; Evrysdi for spinal muscular atrophy; Tysabri for neurological disease; Trelegy for respiratory disease; and Tremfya for immunology conditions. Other marketed royalty assets include Xtandi, Imbruvica, Cabometyx/Cometriq, Trodelvy, Spinraza and Amvuttra. [P146465215][P146465217]\n\nThe portfolio also contains development-stage assets, rather than marketed products, including daraxonrasib, a RAS(ON) inhibitor being studied for pancreatic and lung cancers; deucrictibant, an oral bradykinin B2 antagonist being developed for hereditary angioedema; olpasiran and pelacarsen, candidates targeting lipoprotein(a); trontinemab for Alzheimer’s disease; and tividenofusp alfa, an enzyme-replacement candidate for Hunter syndrome. [T9652309]\n\nRoyalty receipts are generally linked to sales of the associated medicines, while the companies marketing those medicines retain responsibility for commercialization, manufacturing and marketing. In the first half of 2026, the five largest product franchises represented 59% of Royalty Receipts; no individual product represented more than 26% of 2025 Portfolio Receipts. [P146465063][P146465443][P121742038]\n[P146465215][P146465217][T9652309][P146465063][P146465443][P121742038]", "updatedAt": "2026-10-02T11:13:45.638182Z" }, { "type": "GEOGRAPHY", "text": "Royalty Pharma is headquartered in New York City, with executive offices at 110 East 59th Street; its official contact listing specifies Floor 33. [P99901963][https://www.royaltypharma.com/investors/contact-us/]\n\nIts royalty-generating assets are tied primarily to pharmaceutical-product sales in the United States, Europe, and the rest of the world. The company does not provide a revenue or royalty-receipts breakdown by country or region, and no employee distribution by geography is reported in the sources reviewed. [P120220071]\n[P99901963][https://www.royaltypharma.com/investors/contact-us/][P120220071][https://www.royaltypharma.com/investors/contact-us/]", "updatedAt": "2026-10-02T11:13:45.638182Z" }, { "type": "SEGMENTS", "text": "Royalty Pharma plc reports one operating and reportable segment, focused primarily on acquiring biopharmaceutical royalties. Accordingly, the sole reported segment represents 100% of the company’s segment reporting; the company does not disclose separate segment contributions by therapeutic area. [P146464743][P84078400]\n\nIts royalty portfolio spans therapies in rare diseases, neuroscience, oncology, hematology, immunology, respiratory disease and diabetes. These are portfolio focus areas, not separately reported business segments, and the company does not provide revenue percentages for them as segments. [P121742038]\n[P146464743][P84078400][P121742038]", "updatedAt": "2026-10-02T11:13:45.638182Z" }, { "type": "HISTORY", "text": "Founded in 1996 by Pablo Legorreta, Royalty Pharma began investing in pharmaceutical royalties; its first investment was reportedly a $20 million royalty interest related to Neupogen. [https://www.royaltypharma.com/our-firm/meet-the-team/pablo-legorreta/][https://www.royaltypharma.com/wp-content/uploads/2023/12/RPRX-USQ_Transcript_2022-05-17-1.pdf] In 2004, the business adopted an evergreen structure and established its first pharmaceutical-royalty-backed securitization facility. [https://www.sec.gov/Archives/edgar/data/1802768/000119312520150246/d862976ds1.htm] A notable later expansion came in 2014, when it agreed to acquire the Cystic Fibrosis Foundation’s royalties on Vertex cystic-fibrosis treatments for $3.3 billion. [https://www.royaltypharma.com/news/royalty-pharma-announces-33-billion-royalty-transaction-cystic/]\n\nIn June 2020, Royalty Pharma completed its initial public offering and began trading on Nasdaq under the symbol RPRX. [https://www.royaltypharma.com/news/royalty-pharma-announces-pricing-initial-public-offering/][https://www.royaltypharma.com/news/royalty-pharma-announces-closing-initial-public-offering/] In 2025, it completed the acquisition of RP Management, its external manager, bringing management in-house. [P8963677][https://www.royaltypharma.com/news/royalty-pharma-completes-the-acquisition-of-its-external-manager/]\n[P8963677][https://www.royaltypharma.com/our-firm/meet-the-team/pablo-legorreta/][https://www.royaltypharma.com/wp-content/uploads/2023/12/RPRX-USQ_Transcript_2022-05-17-1.pdf][https://www.sec.gov/Archives/edgar/data/1802768/000119312520150246/d862976ds1.htm][https://www.royaltypharma.com/news/royalty-pharma-announces-33-billion-royalty-transaction-cystic/][https://www.royaltypharma.com/news/royalty-pharma-announces-pricing-initial-public-offering/][https://www.royaltypharma.com/news/royalty-pharma-announces-closing-initial-public-offering/][https://www.royaltypharma.com/news/royalty-pharma-completes-the-acquisition-of-its-external-manager/]", "updatedAt": "2026-10-02T11:13:45.638182Z" } ], "sources": [ { "id": "P97551930", "href": "https://app.finbar.com/go?id=P97551930", "label": "Royalty Pharma plc — Full financial report (2025 Y)", "documentId": "D-3e93fc7218e24cd1b6f35162293dabf1" }, { "id": "P146465211", "href": "https://app.finbar.com/go?id=P146465211", "label": "Royalty Pharma plc — Full financial report (2026 Q 2)", "documentId": "D-9e8d698277f9405db221a354c0bd5c3f" }, { "id": "P100719992", "href": "https://app.finbar.com/go?id=P100719992", "label": "Royalty Pharma plc — Full financial report (2025 Y)", "documentId": "D-3e93fc7218e24cd1b6f35162293dabf1" }, { "id": "https://www.royaltypharma.com/our-firm/", "href": "https://www.royaltypharma.com/our-firm/", "label": "www.royaltypharma.com" }, { "id": "P146465215", "href": "https://app.finbar.com/go?id=P146465215", "label": "Royalty Pharma plc — Full financial report (2026 Q 2)", "documentId": "D-9e8d698277f9405db221a354c0bd5c3f" }, { "id": "T9032949", "href": "https://app.finbar.com/go?id=T9032949", "label": "Royalty Pharma plc — Full financial report (2025 Y)", "documentId": "D-3e93fc7218e24cd1b6f35162293dabf1" }, { "id": "P70126503", "href": "https://app.finbar.com/go?id=P70126503", "label": "Royalty Pharma plc — Full financial report (2025 Y)", "documentId": "D-3e93fc7218e24cd1b6f35162293dabf1" }, { "id": "T7144074", "href": "https://app.finbar.com/go?id=T7144074", "label": "Royalty Pharma plc — Full financial report (2025 Y)", "documentId": "D-3e93fc7218e24cd1b6f35162293dabf1" }, { "id": "https://stockanalysis.com/stocks/rprx/employees/", "href": "https://stockanalysis.com/stocks/rprx/employees/", "label": "stockanalysis.com" }, { "id": "P146465217", "href": "https://app.finbar.com/go?id=P146465217", "label": "Royalty Pharma plc — Full financial report (2026 Q 2)", "documentId": "D-9e8d698277f9405db221a354c0bd5c3f" }, { "id": "T9652309", "href": "https://app.finbar.com/go?id=T9652309", "label": "Royalty Pharma plc — Full financial report (2025 Y)", "documentId": "D-3e93fc7218e24cd1b6f35162293dabf1" }, { "id": "P146465063", "href": "https://app.finbar.com/go?id=P146465063", "label": "Royalty Pharma plc — Full financial report (2026 Q 2)", "documentId": "D-9e8d698277f9405db221a354c0bd5c3f" }, { "id": "P146465443", "href": "https://app.finbar.com/go?id=P146465443", "label": "Royalty Pharma plc — Full financial report (2026 Q 2)", "documentId": "D-9e8d698277f9405db221a354c0bd5c3f" }, { "id": "P121742038", "href": "https://app.finbar.com/go?id=P121742038", "label": "Royalty Pharma plc — Full financial report (2025 Y)", "documentId": "D-3e93fc7218e24cd1b6f35162293dabf1" }, { "id": "P99901963", "href": "https://app.finbar.com/go?id=P99901963", "label": "Royalty Pharma plc — Full financial report (2025 Y)", "documentId": "D-3e93fc7218e24cd1b6f35162293dabf1" }, { "id": "https://www.royaltypharma.com/investors/contact-us/", "href": "https://www.royaltypharma.com/investors/contact-us/", "label": "www.royaltypharma.com" }, { "id": "P120220071", "href": "https://app.finbar.com/go?id=P120220071", "label": "Royalty Pharma plc — Full financial report (2025 Y)", "documentId": "D-3e93fc7218e24cd1b6f35162293dabf1" }, { "id": "P146464743", "href": "https://app.finbar.com/go?id=P146464743", "label": "Royalty Pharma plc — Full financial report (2026 Q 2)", "documentId": "D-9e8d698277f9405db221a354c0bd5c3f" }, { "id": "P84078400", "href": "https://app.finbar.com/go?id=P84078400", "label": "Royalty Pharma plc — Full financial report (2025 Y)", "documentId": "D-3e93fc7218e24cd1b6f35162293dabf1" }, { "id": "https://www.royaltypharma.com/our-firm/meet-the-team/pablo-legorreta/", "href": "https://www.royaltypharma.com/our-firm/meet-the-team/pablo-legorreta/", "label": "www.royaltypharma.com" }, { "id": "https://www.royaltypharma.com/wp-content/uploads/2023/12/RPRX-USQ_Transcript_2022-05-17-1.pdf", "href": "https://www.royaltypharma.com/wp-content/uploads/2023/12/RPRX-USQ_Transcript_2022-05-17-1.pdf", "label": "www.royaltypharma.com" }, { "id": "https://www.sec.gov/Archives/edgar/data/1802768/000119312520150246/d862976ds1.htm", "href": "https://www.sec.gov/Archives/edgar/data/1802768/000119312520150246/d862976ds1.htm", "label": "www.sec.gov" }, { "id": "https://www.royaltypharma.com/news/royalty-pharma-announces-33-billion-royalty-transaction-cystic/", "href": "https://www.royaltypharma.com/news/royalty-pharma-announces-33-billion-royalty-transaction-cystic/", "label": "www.royaltypharma.com" }, { "id": "https://www.royaltypharma.com/news/royalty-pharma-announces-pricing-initial-public-offering/", "href": "https://www.royaltypharma.com/news/royalty-pharma-announces-pricing-initial-public-offering/", "label": "www.royaltypharma.com" }, { "id": "https://www.royaltypharma.com/news/royalty-pharma-announces-closing-initial-public-offering/", "href": "https://www.royaltypharma.com/news/royalty-pharma-announces-closing-initial-public-offering/", "label": "www.royaltypharma.com" }, { "id": "P8963677", "href": "https://app.finbar.com/go?id=P8963677", "label": "Royalty Pharma plc — Full financial report (2025 Y)", "documentId": "D-3e93fc7218e24cd1b6f35162293dabf1" }, { "id": "https://www.royaltypharma.com/news/royalty-pharma-completes-the-acquisition-of-its-external-manager/", "href": "https://www.royaltypharma.com/news/royalty-pharma-completes-the-acquisition-of-its-external-manager/", "label": "www.royaltypharma.com" } ] }